EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China Insulin Glargine Market, 2009-2018

  • ID: 2769105
  • Report
  • February 2014
  • Region: China
  • 40 Pages
  • China Research & Intelligence
1 of 4
With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has become a heavy burden on individuals, families, society and governments.

According to statistics from IDF (International Diabetes Federation), the global prevalence rate of diabetes among adults aged 20 to 79 was 8.3% in 2013. The number of diabetes patients has reached 382 million, of which 80% are from medium- and low-income countries where it is still rising rapidly.

It is estimated that by 2035 there will be nearly 592 million people worldwide suffering from diabetes. In the evaluation of diabetes incidence and its trend among various countries and regions, China ranked the first with 98.4 million diabetes patients in 2013, followed by India (65.1 million), the U.S.A. (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that the number of diabetes patients in China will reach 143 million by 2035, which will still be the highest worldwide while that in the U.S.A. will merely reach 29.7 million. Rapid growth of diabetes in China and other developing countries has become an extraordinarily serious burden for these countries' social and economic development.

Insulin glargine is the first long-acting insulin analogue produced through recombinant DNA technology. It was approved for use by FDA (Food and Drug Administration) in April 2000 and EMEA (European Medicines Evaluation Agency) in June 2000. As there is no apparent peak in long-term use of insulin glargine, it has become the most widely used insulin in the United States.

In China, the third-generation insulin is under promotion. Because of the relatively high price, it is mainly used in first-tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition.

Based on CRI's research about certain sample hospitals in China, the CAGR (compound annual growth rate) of sales value of insulin glargine in Chinese sample hospital market exceeded 70% from 2005 to 2013. Human insulin is produced through genetic engineering methods, so a relatively high threshold of production technology is formed. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap, so manufacturers have to attain an industrial production of large scale, low cost and mature technology before gaining profit. At present, Chinese market is mainly occupied by LANTUS produced by Aventis Behring GmbH and Basalin by Gan & Lee Pharmaceuticals. However, changes of global market pattern are expected to happen in the next few years. On the one hand, in the global market, MSD Co., Ltd. is working with Samsung Bioepis to develop LANTUS. The two companies declared on Feb 10, 2014 that the product will soon launch the third phase clinical trial on Type I and Type II diabetes. Presently, LANTUS generic drug produced by Eli Lilly and Company has come to the late-stage clinical trials. On the other hand, in Chinese market, some local businesses are also hastening the development of LANTUS generic drug.

As Chinese people's living standard improves and lifestyles change, incidence of diabetes continuously goes up, resulting in the year-after-year expanding of diabetes drug market in the country. According to CRI's investigation, total sales value of diabetes drug market in China surpassed CNY 18 billion in 2013. In China, the second-generation recombinant human insulin is still the market mainstream. However, as the third-generation insulin products are more technically advanced comparing with the second-generation by diminishing certain defects and shortening curing time effectively, it is expected to replace the second-generation in the near future. As a product with most growth potential among the three generations of insulin products in China, insulin glargine is expected to get more and more attention.

Through this report, the readers can acquire the following information:

- Market Share of Major Insulin Glargine Manufacturers in Sample Hospitals in China
- Sales Price of Insulin Glargine in Hospital Market in China
- Major Insulin Glargine Enterprises in China
- Market Share of Insulin Glargine by Dosage Form in Hospital Market in China
- Prospect of China Insulin Glargine Market

The author recommends the report to the following:

- Insulin Glargine API and Finished Product Manufacturers
- Medical Institutions
- Investors /Research Agencies Focusing on Insulin Glargine Market
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1 Relevant Concepts of Insulin Glargine
1.1 Indication
1.2 Sales Status on the Global Market

2 Market Overview of Insulin Glargine in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Insulin Glargine in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Insulin Glargine Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Insulin Glargine by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form

6 Reference Price of Insulin Glargine in Hospital Market in China, 2013
6.1 Insulin Glargine (LANTUS) Produced by Aventis Behring GmbH
6.2 Insulin Glargine (Basalin) Produced by Gan & Lee Pharmaceuticals

7 Major Manufacturing Enterprises in China Insulin Glargine Market, 2009-2013
7.1 Aventis Behring GmbH
7.2 Gan & Lee Pharmaceuticals

8 Prospect of China Insulin Glargine Market, 2014-2018
8.1 Trend of Diabetes Incidence
8.2 Forecast on Market Size
8.3 Forecast on Competition Pattern
8.4 Generic Drugs in Research

Selected Charts

Chart Insulin Glargine Products Approved to Market in China, 2014
Chart Sales Value of Insulin Glargine in Global Market, 2009-2013
Chart Sales Value of Insulin Glargine in Hospital Market in China, 2009-2013
Chart Sales Value of Insulin Glargine by Region in China, 2009-2013
Chart Market Share of Insulin Glargine Enterprises by Sales Value in China, 2009-2013
Chart Forecast on Market Size of Hospital-used Insulin Glargine in China, 2014-2018
Chart Price of Insulin Glargine Produced by Aventis Behring GmbH in Hospital Market
Chart Price of Insulin Glargine Produced by Gan & Lee Pharmaceuticals in Hospital Market
Note: Product cover images may vary from those shown
3 of 4
- Aventis Behring GmbH
- Gan & Lee Pharmaceuticals
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll